Hyperinsulinaemia as a cause of obesity and cardiometabolic diseases
March 9, 2026 / Hyperinsulinaemia / Obesity Pathophysiology / Cardiometabolic Disease / Insulin Resistance / Metabolic Health
Chronic basal hyperinsulinaemia may independently drive adiposity and cardiometabolic disease beyond normal postprandial insulin responses. Evidence from human and preclinical studies highlights genetic, dietary, environmental, and lifestyle contributors, underscoring prevention gaps and the need to clarify insulin’s causal role in obesity.
MetaVia to Highlight Novel Obesity and Metabolic Therapies at Upcoming Life Sciences Virtual Investor Forum
March 4, 2025 / Obesity Therapeutics / Cardiometabolic Disease / GLP-1 Dual Agonist / MASH Treatment / Metabolic Drug Development
MetaVia will present its cardiometabolic pipeline at the Life Sciences Virtual Investor Forum, highlighting DA-1726, an oxyntomodulin-based GLP-1/glucagon dual agonist for obesity, and vanoglipel, a GPR119 agonist demonstrating metabolic and hepatic benefits for MASH and glucose control.
Circadian rhythm drives metabolic dysfunction in fat cells, study finds
March 9, 2026 / Circadian Rhythm Metabolism / Adipocyte Mitochondrial Dysfunction / Obesity Mechanisms / NAD+ Metabolic Pathways / Metabolic Disease Research
Disruption of circadian rhythm impairs mitochondrial oxidative metabolism in adipocytes via altered BMAL1 signaling, contributing to metabolic dysfunction. Restoring NAD⁺ balance using yeast NDI1 enzyme prevented circadian- and diet-induced metabolic impairment, highlighting potential therapeutic targets for obesity-related metabolic disease.
ADM pet nutrition supplement benefits metabolic health in obese dogs
March 4, 2026 / Pet Metabolic Health / Probiotics and Postbiotics / Canine Obesity Research / Gut Hormone Regulation / Microbiome Nutrition
ADM’s Priome supplement containing Bifidobacterium animalis CECT 8145 showed metabolic biomarker improvements in obese Labrador Retrievers. Probiotic and postbiotic supplementation influenced gut hormone signaling during weight gain and loss, though no significant changes in body weight or composition were observed.
How are GLP-1 drugs reshaping treatment for obesity, diabetes, and heart disease?
March 3, 2026 / GLP-1 Receptor Agonists / Incretin-Based Therapies / Obesity Pharmacotherapy / Cardiometabolic Disease / Type 2 Diabetes Treatment
GLP-1 receptor agonists and next-generation incretin therapies significantly improve glycemic control, induce substantial weight loss, and reduce cardiovascular and renal risk. Emerging dual, triple, and oral agents may deliver up to ~24% weight loss while addressing multiple cardiometabolic disease pathways.
China Approval of Ecnoglutide Expands Competition in the GLP-1 Obesity Market
March 6, 2026 / GLP-1 Receptor Agonists / Obesity Drug Development / Ecnoglutide Approval / Metabolic Disease Therapeutics / Global GLP-1 Market
China approved ecnoglutide, the first cAMP-biased GLP-1 receptor agonist, for chronic weight management, showing ~15% placebo-adjusted weight loss. The approval and Pfizer commercialization partnership position Sciwind as a new competitor in the rapidly expanding global obesity therapeutics market.
Deciphering the causal influence of BMI and related metabolic, inflammatory, and cardiovascular factors on brain structure: a Mendelian Randomization Study
March 9, 2026 / Obesity and Brain Structure / Body Mass Index Effects / Cortical Thickness Decline / Neuroinflammation Biomarkers / Mendelian Randomization Study
Mendelian randomization analysis suggests elevated BMI causally contributes to reduced cortical thickness, particularly in the precentral and fusiform regions. Visceral adiposity and inflammatory marker CRP showed overlapping associations, implicating inflammation and adiposity in obesity-related brain structural decline.
Response Pharmaceuticals Reports Positive 36-Week Phase 2 Data Supporting RDX-002 as a Long-Term Option in Post-GLP-1 Receptor Agonist Weight Management
March 5, 2026 / Post-GLP-1 Weight Management / Obesity Maintenance Therapy / RDX-002 Clinical Trial / Postprandial Triglycerides / Cardiometabolic Risk Reduction
Phase 2 data show RDX-002 preserved 57% of prior GLP-1–induced weight loss at 36 weeks after therapy discontinuation, significantly reducing postprandial triglycerides and weight regain, supporting its potential as a long-term maintenance therapy in chronic obesity management.
Puberty reshapes DNA to worsen or reverse insulin resistance
March 3, 2026 / Puberty Insulin Resistance / DNA Methylation Epigenetics / Pediatric Obesity Risk / Cardiometabolic Disease Development / Type 2 Diabetes Pathogenesis
Epigenetic changes during puberty, particularly DNA methylation patterns, influence insulin resistance trajectories in youth. Findings suggest puberty is a critical window where obesity-related epigenetic regulation may worsen or improve insulin sensitivity, shaping long-term cardiometabolic and type 2 diabetes risk.
MetALD: Redefining the overlap of metabolic and alcohol-related liver injury
March 5, 2026 / Metabolic Alcohol-Related Liver Disease / MASLD and ALD Overlap / Liver Fibrosis Pathogenesis / Gut Liver Axis Dysfunction / Cardiometabolic Liver Disease
MetALD defines liver disease driven by combined metabolic dysfunction and moderate alcohol consumption, where synergistic metabolic, inflammatory, and gut–liver mechanisms accelerate steatosis, fibrosis, and liver injury. Management requires simultaneous control of cardiometabolic risk factors and alcohol exposure.
How CO₂-sensing neurons in a worm could eventually protect humans from metabolic stress
March 5, 2026 / Mitochondrial Stress Response / CO2-Sensing Neurons / Metabolic Stress Mechanisms / Cellular Energy Metabolism / Neuro-Metabolic Signaling
Research in C. elegans shows CO₂-sensing neurons can anticipate environmental stress and activate systemic mitochondrial stress responses, protecting cellular energy metabolism. The findings suggest conserved neural pathways that could inform therapies targeting mitochondrial dysfunction and metabolic stress in humans.
Telehealth Meets Weight-Loss Boom: Why Hims & Hers Is Surging on Wegovy Partnership News
MARch 9, 2026 / Telehealth Weight Loss Treatment / GLP-1 Receptor Agonists / Wegovy Semaglutide / Digital Health Prescribing / Obesity Pharmacotherapy Market
Hims & Hers may partner with Novo Nordisk to distribute the GLP-1 agonist semaglutide (Wegovy) via telehealth, highlighting the expanding role of digital healthcare platforms in improving patient access to pharmacologic obesity treatments and chronic weight management.
Pfizer’s weight-loss injection cleared in Chinese market
March 9, 2026 / GLP-1 Receptor Agonists / Ecnoglutide Injection / Obesity Pharmacotherapy / Chronic Weight Management / China Drug Approval
China approved Pfizer’s once-weekly GLP-1 receptor agonist ecnoglutide (Xianweiying) for chronic weight management in adults with overweight or obesity, expanding therapeutic options and intensifying competition in the rapidly growing obesity pharmacotherapy market.
Apollo doctor shares 5 ways to reverse obesity without extreme dieting
March 3, 2026 / Obesity Lifestyle Management / Cardiometabolic Disease Prevention / Sustainable Weight Loss / Obesity Pharmacotherapy / Bariatric Surgery Treatment
Obesity is a chronic metabolic disease linked to cardiometabolic complications. Evidence-based management emphasizes sustainable lifestyle interventions—balanced nutrition, regular physical activity, adequate sleep, and stress control—with pharmacotherapy or bariatric surgery considered for patients with severe or treatment-resistant obesity.
Bariatric Surgery Emerges as a Vital Lifeline for Obesity Patients
March 5, 2025 / Bariatric Surgery Treatment / Severe Obesity Management / Type 2 Diabetes Remission / Metabolic Weight Loss Surgery / Cardiometabolic Risk Reduction
Bariatric surgery is increasingly recognized as a life-saving treatment for severe obesity, producing sustained weight loss and metabolic improvements. Procedures such as gastric bypass and sleeve gastrectomy can induce remission of type 2 diabetes and reduce long-term cardiometabolic disease risk.
Chennai hospital launches programme to curb metabolic diseases
March 8, 2026 / Precision Medicine Metabolic Disease / Genomic Lifestyle Counselling / Nutrigenomics Personalized Nutrition / Type 2 Diabetes Prevention / Cardiometabolic Risk Management
Dr. Mohan’s Diabetes Specialities Centre launched a Genomic Lifestyle Counselling program using genetic testing to personalize diet, exercise, and lifestyle interventions, supporting precision prevention and management of metabolic diseases such as type 2 diabetes, obesity, and cardiovascular disorders.
Human trial testing gene silencing injection therapy for MASH kicks off
March 9, 2026 / MASH Gene Silencing Therapy / siRNA Liver Treatment / Metabolic Dysfunction Associated Steatohepatitis / RNA Therapeutics Clinical Trial / Liver Fibrosis Drug Development
A Phase 1/2 clinical trial has begun evaluating TGM-312, a GalNAc-delivered siRNA therapy designed to silence disease-driving genes in liver cells for metabolic dysfunction-associated steatohepatitis (MASH), targeting hepatic steatosis, inflammation, and fibrosis progression.
Boehringer steps back from MASH programm as OSE restructure its pipeline
March 4, 2026 / MASH Drug Development / Anti SIRPα Antibody / Phase II Clinical Failure / Metabolic Liver Disease Research / Biotech Pipeline Strategy
Boehringer Ingelheim discontinued development of the anti-SIRPα antibody BI 770371 for MASH after a Phase II efficacy failure. OSE Immunotherapeutics will refocus resources on oncology and immunology programs while halting several early-stage metabolic and inflammatory pipeline assets.
Madrigal Pharmaceuticals Announces Grants of Inducement Awards under Nasdaq Listing Rule 5635(c)(4)
March 5, 2025 / MASH Drug Development / Metabolic Liver Disease Therapeutics / Biopharmaceutical Equity Incentives / Madrigal Pharmaceuticals / Steatohepatitis Research Pipeline
Madrigal Pharmaceuticals granted equity inducement awards to new employees under its 2025 Inducement Plan, supporting talent recruitment as the company advances development of therapies targeting metabolic dysfunction-associated steatohepatitis (MASH) and related metabolic liver diseases.